Non-aqueous oil-in-oil solvent evaporation technique is used for the preparation of polycaprolactone microspheres loaded with the antibiotic metronidazole by introducing different masses for the drug. The prepared microspheres are characterized by calculating drug encapsulation and drug loading percentages, measuring the corresponding particle size, performing FT-IR polymer-drug compatibility study and in vitro drug release. Moderate drug encapsulation values with a maximum of 34% are observed due to the low molecular weight of the drug. Microspheres had a particle size ranging between 130 and 280 µm with a spherical profile and porous structure. FT-IR study showed no interactions between the drug and the polymer. Drug release studies showed fast release rates for all the formulations with the slowest release for the highest drug loading.
INTRODUCTION
Targeted drug delivery is a not a new concept in therapy, it dates back to 1906. The challenge is to create a medicine that targets only specific sites in the human body. This drug must be effective, and carried to the specific site without avoiding the immunogenic system 1-4 . Using biodegradable and biocompatible polymers in targeted drug delivery has many advantages such as providing sustained delivery of the drug, its localized delivery and its stability. Different kinds of drugs can be encapsulated in various types of polymers depending on their chemical and physical characteristics. One of the most common techniques used for microencapsulation is the solvent evaporation used for both hydrophobic and hydrophilic drugs. It has many advantages because it requires only simple experimental conditions like heat and stirring 5, 6 . Metronidazole (MTZ) is an antibiotic used against anaerobic bacteria and certain parasites. Metronidazole has a broad spectrum of protozoal and antimicrobial activity, both locally and synthetically 7 . Treatment using MTZ could induce some reported side effects such as epigastric pain, mouth dryness, nausea and others. In order to decrease these adverse effects, in addition to deliver the drug to the site of infection for a longer period and reach the best antibiotic efficiency, MTZ polymeric microspheres could be formulated 8 .
Polycaprolactone (PCL) belongs to the family of polyesters. It is highly miscible in organic solvents. In addition, it adheres well to a large number of surfaces, which enabled it to be used widely in several medical applications 9-11 . PCL is nontoxic and semicrystalline with high organic solvent solubility. Due to the polymer very low degradation rate and high drug permeability, it has been extensively used in the medical field in implant devices in tissue engineering and in drug delivery devices 12, 13 .
In this study, MTZ microspheres formulations are prepared using non-aqueous o/o emulsion solvent evaporation technique with PCL as the coating polymer. Microspheres are then characterized for drug loading, drug encapsulation, particle size, drug-polymer interaction and in vitro drug release.
EXPERIMENTAL
Materials used include the polymer, Poly-ɛ-caprolactone (average MW 80,000), the drug Metronidazole, the surfactant Span 80, and Phosphate Buffered Saline (PBS) (0.2 M, pH 7.4). They are purchased from Sigma-Aldrich, Chemie, Germany. Paraffin Oil, dichloromethane (DCM), Methanol (MeOH) and n-hexane are of analytical grade. . 25 mg microspheres are introduced in dialysis bags having a molecular weight cut off of 12000-14000. These were suspended in 15 ml PBS at 37°C. At different time intervals, 1 ml of the release medium is withdrawn and replaced with fresh solution and tested for its drug content at 311 nm.
RESULTS AND DISCUSSION
Non-aqueous solvent evaporation method was applied for the preparation of MTZ-loaded PCL microspheres. Since MTZ is water soluble, the oil-in-oil method was chosen. It consists of adding the organic active phase containing the drug into another organic phase containing the hydrophobic surfactant Span 80. This method is preferred in the case of MTZ in order to avoid the loss of drug during microencapsulation step and improve drug encapsulation and bioavailability compared to hydrophobic drugs where an aqueous phase is used instead 14 .
Morphology of microspheres:
SEM microphotographs of the prepared samples showed a homogeneous reproducible spherical profile with a porous structure of the polymeric matrix (Figure 1 ).
Figure 1: SEM microphotographs of microspheres at 500x magnifications

Drug content and size of microspheres:
Microspheres formulations were prepared by changing the drug mass between 50 and 200 mg. For each mass, %DE and %DL were calculated along with the average particle size. Results are presented in Table 1 . PCL microspheres loaded with MTZ had a particle size ranging between 131 and 280 µm (Table 1) . In comparison to other drugs encapsulated in PCL such as Amphotericin B, and prepared using an aqueous phase and a hydrophilic surfactant, microspheres had a particle size ranging between 110 µm and 125 µm 11 . This difference could be attributed to the fact that the organic solvent DCM used in preparing MTZ microspheres has a higher solubility in Paraffin oil than in water. This leads to a faster mass transfer between the two dispersed and continuous phases, leading to rapid precipitation of microspheres and thus larger particles 15, 16 .
Concerning the drug content of microspheres, the maximum %DE and % DL were 34% and 1.5% respectively. They were attributed to formulation M3 containing 100 mg drug. Drug In the case of Metronidazole, it has a low molecular weight, which is about 171 g/mol. Thus, diffusion out of the microspheres could have occurred yielding low %DE and %DL 18, 19 .
Drug-polymer compatibility study:
FT-IR study could confirm the chemical stability of MTZ encapsulated in PCL microspheres. This is done by measuring the characteristic peak shifts of the loaded microspheres in comparison with these of pure drug MTZ and polymer PCL. Recorded spectra are presented in Figure  3 .
Figure 3: FT-IR spectra of MTZ (a), PCL (b) and PCL MTZ-loaded microspheres (c)
MTZ characteristic peaks are showing at 3220 cm -1 and assigned to stretching -OH, 3099 cm -1 to stretching =CH, 1073 cm -1 to stretching -C-O of -C-OH (Figure 3a ) 20 .
Important bands are also showing in the spectrum of PCL (Figure 3b ). Peak at 2943 cm -1 is assigned to stretching of -C-H bending alkane. The peak at 1721 cm -1 corresponds to stretching of -C=O carbonyl 21 .
The representative peaks of MTZ and PCL didn't show any significant shifting and are present in the spectrum of loaded microspheres (Figure 3c ). This indicated that the microencapsulation process didn't change the chemical structure of the drug and there were no chemical interactions observed between the drug and the polymer.
In vitro release study: Figure 4 shows the In vitro release profiles of the different formulations prepared. The study reveals that the release rate is fast for all the formulations and requires minutes to go to completion. This could be explained by the fact that the drug MTZ used is water soluble. It has a good affinity towards the PBS release medium, and thus it tends to escape easily and be diffused out of the porous polymeric matrix within a short time 22 . In addition, the sample containing 100 mg drug, which is characterized by the highest %DL, has the slowest release rate and required 80 minutes to get completely released. show that the release rate becomes slower with the increase in drug content. In fact, at higher loadings, the chances of drug particles inside the polymer matrix to contact each other are high. This causes the formation of aggregates that need more time to dissolve, and thus more time for the drug to be released 23 . 
CONCLUSION
The non-aqueous o/o solvent evaporation method was used to prepare metronidazole-loaded Polycaprolactone microspheres. Moderate drug encapsulation values with a maximum of 34% are observed. Microspheres had a particle size ranging between 130 and 280 µm with a spherical profile and porous structure. FT-IR study showed no interactions between the drug and the polymer. Drug release studies showed fast release rates for all the formulations with the slowest release for the highest drug loading.
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